

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1467680
<b>Application Number:</b>	10551501
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8326
<b>Title of Invention:</b>	Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
<b>First Named Inventor/Applicant Name:</b>	Nicola Mary Aston
<b>Customer Number:</b>	20462
<b>Filer:</b>	Dara L. Dinner/Christina Boyer
<b>Filer Authorized By:</b>	Dara L. Dinner
<b>Attorney Docket Number:</b>	PB60196
<b>Receipt Date:</b>	26-JAN-2007
<b>Filing Date:</b>	25-MAY-2006
<b>Time Stamp:</b>	11:36:52
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$450
RAM confirmation Number	1425
Deposit Account	192570
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

### File Listing:

---

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1		60196oa1.pdf	149306	yes	18
	<b>Multipart Description/PDF files in .zip description</b>				
	<b>Document Description</b>		<b>Start</b>		<b>End</b>
	Amendment - After Non-Final Rejection		1		1
	Claims		2		13
	Applicant Arguments/Remarks Made in an Amendment		14		16
	Terminal Disclaimer Filed		17		18
<b>Warnings:</b>					
<b>Information:</b>					
2	Information Disclosure Statement (IDS) Filed	IDSJan07.pdf	74258	no	4
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
3	Information Disclosure Statement (IDS) Filed	PTO1449formJan07.pdf	169706	no	4
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
4	Foreign Reference	WO06110173.pdf	5956914	no	130
<b>Warnings:</b>					
<b>Information:</b>					
5	Foreign Reference	JP11218884.pdf	2983981	no	142
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	wo9857934.pdf	7566193	no	165
<b>Warnings:</b>					

<b>Information:</b>					
7	NPL Documents	CourtenyBioorgMedChem2004.pdf	273935	no	5
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	FosterDrugNewsPersp.pdf	216676	no	10
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	HenryBioorgMedChem1998.pdf	299003	no	6
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	MarinBlood98_3.pdf	171078	no	7
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	HerlaarMolecularMedicineToday5.pdf	261737	no	9
<b>Warnings:</b>					
<b>Information:</b>					
12	Fee Worksheet (PTO-06)	fee-info.pdf	8180	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			18130967		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					